Literature DB >> 21036542

Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis.

Michael T Compton1, Beth Broussard, Claire E Ramsay, Tarianna Stewart.   

Abstract

INTRODUCTION: Limited research indicates that pre-illness cannabis use may result in an earlier age at onset of psychosis, though little is known about the influence of prior cannabis use on the premorbid and prodromal phases. This study examined the effects of prior or concurrent cannabis (as well as nicotine and alcohol) use on: (1) early adolescent (12-15 years) premorbid functioning, (2) late adolescent (16-18 years) premorbid functioning, (3) two features of the prodrome, and (4) mode of onset of psychosis.
METHODS: Participants included 109 well-characterized first-episode patients hospitalized in public-sector settings. Assessments included ages at initiation of first, weekly, and daily use of substances, the Premorbid Adjustment Scale, the Symptom Onset in Schizophrenia inventory, and a consensus-based best estimate of mode of onset.
RESULTS: Participants having used cannabis at ≤15 years had better early adolescence social functioning than those who had not used cannabis (p=0.02). Conversely, those who had used cannabis at ≤18 years had poorer late adolescence academic functioning (p<0.001). Participants having used cannabis before onset of psychotic symptoms did not differ from those who had not in terms of having had an identifiable prodrome or the number of prodromal symptoms experienced. Whereas 42% of those having used cannabis daily had an acute mode of onset of psychosis, only 20% of those without prior daily cannabis use had an acute onset (p=0.04).
CONCLUSIONS: Findings suggest that cannabis use is associated with premorbid social and academic functioning and mode of onset. Further research is warranted to elucidate the complex associations between cannabis use and diverse early-course features.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21036542      PMCID: PMC3052993          DOI: 10.1016/j.schres.2010.10.005

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  41 in total

1.  Substance misuse in first-episode psychosis: 15-month prospective follow-up study.

Authors:  D Wade; S Harrigan; J Edwards; P M Burgess; G Whelan; P D McGorry
Journal:  Br J Psychiatry       Date:  2006-09       Impact factor: 9.319

2.  Substance abuse in first-episode non-affective psychosis.

Authors:  Tor K Larsen; Ingrid Melle; Bjørn Auestad; Svein Friis; Ulrik Haahr; Jan Olav Johannessen; Stein Opjordsmoen; Bjørn Rishovd Rund; Erik Simonsen; Per Vaglum; Thomas H McGlashan
Journal:  Schizophr Res       Date:  2006-09-12       Impact factor: 4.939

3.  Cannabis use and schizophrenia.

Authors:  Darryl Wade
Journal:  Am J Psychiatry       Date:  2005-02       Impact factor: 18.112

4.  Prevalence of substance misuse in first-episode psychosis.

Authors:  R Cantwell; J Brewin; C Glazebrook; T Dalkin; R Fox; I Medley; G Harrison
Journal:  Br J Psychiatry       Date:  1999-02       Impact factor: 9.319

5.  Comorbid substance use and age at onset of schizophrenia.

Authors:  Thomas R E Barnes; Stanley H Mutsatsa; Sam B Hutton; Hilary C Watt; Eileen M Joyce
Journal:  Br J Psychiatry       Date:  2006-03       Impact factor: 9.319

6.  Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis.

Authors:  Carol L M Caton; Deborah S Hasin; Patrick E Shrout; Robert E Drake; Boanerges Dominguez; Michael B First; Sharon Samet; Bella Schanzer
Journal:  Br J Psychiatry       Date:  2007-02       Impact factor: 9.319

7.  Cannabis as a risk factor for psychosis: systematic review.

Authors:  David M Semple; Andrew M McIntosh; Stephen M Lawrie
Journal:  J Psychopharmacol       Date:  2005-03       Impact factor: 4.153

8.  Family-level predictors and correlates of the duration of untreated psychosis in African American first-episode patients.

Authors:  Michael T Compton; Sandra M Goulding; Tynessa L Gordon; Paul S Weiss; Nadine J Kaslow
Journal:  Schizophr Res       Date:  2009-10-14       Impact factor: 4.939

9.  Prevalence and correlates of school drop-out prior to initial treatment of nonaffective psychosis: further evidence suggesting a need for supported education.

Authors:  Sandra M Goulding; Victoria H Chien; Michael T Compton
Journal:  Schizophr Res       Date:  2009-09-24       Impact factor: 4.939

10.  Patterns of substance abuse in schizophrenia: nature and significance.

Authors:  J R DeQuardo; C F Carpenter; R Tandon
Journal:  J Psychiatr Res       Date:  1994 May-Jun       Impact factor: 4.791

View more
  13 in total

Review 1.  Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.

Authors:  Marc W Manseau; Donald C Goff
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 2.  The prodrome and clinical risk for psychotic disorders.

Authors:  Sandra M Goulding; Carrie W Holtzman; Hanan D Trotman; Arthur T Ryan; Allison N Macdonald; Daniel I Shapiro; Joy L Brasfield; Elaine F Walker
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2013-06-18

3.  Measuring trauma and stressful events in childhood and adolescence among patients with first-episode psychosis: initial factor structure, reliability, and validity of the Trauma Experiences Checklist.

Authors:  Sarah L Cristofaro; Sean D Cleary; Claire Ramsay Wan; Beth Broussard; Colby Chapman; Patrick J Haggard; Sara Jananeh; Neely L Myers; Michael T Compton
Journal:  Psychiatry Res       Date:  2013-07-11       Impact factor: 3.222

Review 4.  Evaluation and treatment of children and adolescents with psychotic symptoms.

Authors:  Sibel Algon; James Yi; Monica E Calkins; Christian Kohler; Karin E Borgmann-Winter
Journal:  Curr Psychiatry Rep       Date:  2012-04       Impact factor: 5.285

5.  Relationship between patterns of cannabis use and functional and symptomatic trajectories in first-episode psychosis.

Authors:  Abigail C Wright; Julia Browne; Corinne Cather; Piper Meyer-Kalos; Kim T Mueser
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-07-28       Impact factor: 5.760

6.  Does change in cannabis use in established psychosis affect clinical outcome?

Authors:  Christine Barrowclough; Richard Emsley; Emily Eisner; Ruth Beardmore; Til Wykes
Journal:  Schizophr Bull       Date:  2011-10-29       Impact factor: 9.306

7.  Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use.

Authors:  Laura Ferraro; Caterina La Cascia; Diego Quattrone; Lucia Sideli; Domenica Matranga; Veronica Capuccio; Giada Tripoli; Charlotte Gayer-Anderson; Craig Morgan; Musa B Sami; Pak Sham; Lieuwe de Haan; Eva Velthorst; Hannah E Jongsma; James B Kirkbride; Bart P F Rutten; Alexander L Richards; Laura Roldan; Celso Arango; Miquel Bernardo; Julio Bobes; Julio Sanjuan; Jose Luis Santos; Manuel Arrojo; Ilaria Tarricone; Andrea Tortelli; Andrei Szöke; Cristina Marta Del-Ben; Jean-Paul Selten; Michael Lynskey; Peter B Jones; Jim Van Os; Daniele La Barbera; Robin M Murray; Marta Di Forti
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

8.  Psychological interventions for psychosis in adolescents.

Authors:  Soumitra S Datta; Rhea Daruvala; Ajit Kumar
Journal:  Cochrane Database Syst Rev       Date:  2020-07-03

9.  A clinical comparison of schizophrenia with and without pre-onset cannabis use disorder: a retrospective cohort study using categorical and dimensional approaches.

Authors:  Samuel Sarrazin; Florence Louppe; Raphael Doukhan; Franck Schürhoff
Journal:  Ann Gen Psychiatry       Date:  2015-12-10       Impact factor: 3.455

Review 10.  Pathways from cannabis to psychosis: a review of the evidence.

Authors:  Jonathan K Burns
Journal:  Front Psychiatry       Date:  2013-10-14       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.